Financial Consulate’s Trevi Therapeutics TRVI Stock Holding History

Financial Consulate’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.29K	Buy	+160	New	+$2.75K	﹤0.01%	1087

Other funds holding TRVI

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Financial Consulate's TRVI Position: Q3 2026 in Review

Financial Consulate opened a new position in Trevi Therapeutics (TRVI) in Q3 2026: 160 shares worth $2.29K. The stake represents ﹤0.01% of the portfolio and ranks #1087 among its holdings.

90 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

Financial Consulate held 160 shares of Trevi Therapeutics worth $2.29K as of Q3 2026.
Trevi Therapeutics was a new Financial Consulate position in Q3 2026.
Trevi Therapeutics made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1087 holding.
90 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.